Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter

Haemophilia

Volumn 17, Issue 6, 2011, Pages 846-848

  Morfini, M ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; RIBOSOME DNA; VON WILLEBRAND FACTOR; FACTOR VIII, VON WILLEBRAND FACTOR DRUG COMBINATION;

AREA UNDER THE CURVE; BIOEQUIVALENCE; BLEEDING; BLOOD SAMPLING; DRUG HALF LIFE; GENETIC HETEROGENEITY; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; SUBSTITUTION THERAPY; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE; ARTICLE; DRUG COMBINATION; METABOLIC CLEARANCE RATE; METABOLISM;

DRUG COMBINATIONS; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; METABOLIC CLEARANCE RATE; VON WILLEBRAND FACTOR;

EID: 84857977612     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02663.x     Document Type: Note

References (13)

1. Messori A, Longo G, Morfini M et al. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur J Clin Pharmacol 1988; 35: 663-8.
2. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 12: 3130-7.
3. Menache D, Aronson DL, Darr F et al. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative study group. Br J Haematol 1996; 94: 740-5.
4. ver Elt Kristien MM, van Vielt Huub DM, Kappers-Klunne Mies C, Leebeek Frank WG. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Thromb Haemost 2004; 92: 61-6.
5. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
6. Dobrokovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4(Suppl. 3): 33-9.
7. Goudemand J, Scharrer I, Berntorp E et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005; 3: 2219-27.
8. Menache D. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. Haemophilia 1998; 4(Suppl. 3): 4.
9. Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS, for the Wilate PK. Study Investigators the pharmacokinetic diversity of two von Willebrand factor (VWF)/factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomized crossover study. Thromb Haemost 2011; 106: 279-88.
10. Dl Paola J, Lethagen S, Gill J et al. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value dosing for surgery. Haemophilia 2011; 17: 752-8.
11. Federici AB, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management. Haemophilia 2006; 12(Suppl. 3): 152-8.
12. Federici AB, Castaman G, Mannucci PM, Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
13. Lee M, Morfini M, Schulman S, Ingerslev J. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Available at Accessed September 19, 2011.